ClinicalTrials.gg
CompletedNCT06210919Updated Aug 12, 2025

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

A Phase 1 interventional study of TRTP-101 in Atrophic Scar, sponsored by CellinCells. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by CellinCells · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Cicatrix with a site in Korea, Republic of — 4 open to participants now, 5 under way, none of them phase 3. Cicatrix · Korea, Republic of.

Enrollment
16th of 16
3 · median 28
Started
2023
with 1 other
Phase 1
3 of 20
none open now
Registered
15th of 20
by date
Lead sponsor
6 of 20
CellinCells

Among the 20 studies in Cicatrix with a site in Korea, Republic of, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 15th registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

4 of the 20 studies in Cicatrix with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cicatrix with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.

Read the detailed description

A phase 1 clinical trial to evaluate dose-limiting toxicity by administering a singe dose of TRTP-101 to each of the four sites of atrophic scar.

03

Conditions studied

  • Atrophic Scar

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female aged greater than 19 years
  2. Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose

Exclusion criteria

Exclusion Criteria:

  1. History of cell therapy
  2. Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation
  3. Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting
  4. Positive for virus infection
  5. Use of Anticoagulant therapy or NSAIDs
  6. Thrombocytopenia or other coagulation disorder
  7. History of keloid scars
  8. Infectious disease or other dermatitis in the area of the atrophic scar
  9. Use of , immunomodulating drug, anticancer drug or radiation therapy
  10. Use of systemic medication
  11. History of or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.)
  12. Use of retinoid medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    TRTP-101

    Micro-Block (MiB) manufactured from autologous Adipose-derived Mesenchymal Stem Cells

    Biological: TRTP-101

Interventions

  • BiologicalTRTP-101

    Intradermal injection of the each of four sites

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicity

    Dose Limiting Toxicity is defined as Grade ≥ 3 adverse drug reaction according to CTCAE criteria for 4 weeks after administration of TRTP-101

    Time frame: within 4 weeks

Secondary outcomes

  1. Mean percent change in atrophic scar volume

    The depressed volume of atropic scar is measured at baseline and post-treatment visits

    Time frame: 1, 4, 8 and 12 weeks

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, South Korea
08

References and documents

Publications

  • Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, Bae Y, Park GH. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020 Nov 4;100(18):adv00310. doi: 10.2340/00015555-3666. PubMed 33073298 ↗
  • Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant. 2013;22(2):279-85. doi: 10.3727/096368912X656045. Epub 2012 Sep 21. PubMed 23006344 ↗
  • Salloum RH, Rubin JP, Marra KG. The role of steroids in mesenchymal stem cell differentiation: molecular and clinical perspectives. Horm Mol Biol Clin Investig. 2013 Aug;14(1):3-14. doi: 10.1515/hmbci-2013-0016. PubMed 25436715 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Dec 2024, 12 months.

Of 16 phase 1 interventional studies under Cicatrix, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 17. This study's 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 18, 2024
StartActual
Dec 6, 2023
Primary completionActual
Dec 10, 2024
CompletionActual
Mar 28, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06210919
Lead sponsor
CellinCells
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Dec 6, 2023
Primary completion
Dec 10, 2024
Completion
Mar 28, 2025
Last update
Aug 12, 2025

Study contacts

Jonghee Lee, MD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion